Tyrosine phosphorylation of p27KIP1 correlates with palbociclib responsiveness in breast cancer tumor cells grown in explant culture

Susan R.S. Gottesman, Jonathan Somma, Vladislav Tsiperson, Lisa Dresner, Usha Govindarajulu, Priyank Patel, Stacy W. Blain

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Cdk4-targeting drugs, such as palbociclib, are approved for metastatic ER/PR þ , Her2 breast cancer. However, other than loss of retinoblastoma, which is very rare in this subset, there are no biomarkers to predict response. Cyclin D or cdk4 levels are not by themselves indicative, because p27Kip1 is required for cyclin D–cdk4 complex activation. Tyrosine phosphorylation of p27, including modification on residue Y88 (pY88), activates DK4–p27, and the pY88 level correlates with palbociclib responsiveness in cell lines. We developed dual IHC staining for p27 and pY88, and found that benign breast epithelium was negative, while breast cancer biopsies (of varied hormonal status) could be stratified for pY88 status. Lack of pY88 suggested that DK4 was inactive, and that these samples would not have the target required for palbociclib response. Tumor resection material was grown in explant culture, treated with palbociclib, and stained with Ki67 as a marker of response. Explants from the no pY88 group were nonresponsive, while explants from the low or high pY88 group responded to drug. Implications: Use of the pY88 biomarker, as a surrogate for cdk4 activity, may identify patients responsive to cdk4-targeting drugs and expand use of this therapy.

Original languageEnglish
Pages (from-to)669-675
Number of pages7
JournalMolecular Cancer Research
Volume17
Issue number3
DOIs
StatePublished - 1 Mar 2019
Externally publishedYes

Fingerprint

Dive into the research topics of 'Tyrosine phosphorylation of p27KIP1 correlates with palbociclib responsiveness in breast cancer tumor cells grown in explant culture'. Together they form a unique fingerprint.

Cite this